Rallybio (NASDAQ:RLYB) stock soars 114% after agreeing to sell its stake in a rare bone disorder asset, extending cash runway to mid-2027. Read more here.

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Shares in biotech company Recursion Pharmaceuticals ( RXRX 12.07%) surged by more than 12% by 11 a.m. ET today. The move is ...

A novel QR-RLS constant modulus algorithm called QR-RLS-CMA is proposed. Its potential advantages include numerical stability, computational efficiency and a fast convergence rate. Simulations are ...